Department of Rheumatology, University Hospitals of Derby and Burton NHS Foundation Trust , Derby , UK.
Department of Rheumatology, Barnsley Hospital NHS Foundation Trust , Barnsley , UK.
Expert Opin Pharmacother. 2019 Nov;20(16):1953-1960. doi: 10.1080/14656566.2019.1657404. Epub 2019 Aug 28.
: Psoriatic arthritis (PsA) is a chronic inflammatory condition that is associated with progressive joint destruction and reduced quality of life. Despite the common use of disease-modifying anti-rheumatic drugs (DMARDs) in PsA, their influence has been investigated in a number of studies with conflicting results. There is also concern about their safety and tolerability. Tofacitinib is an orally administered Janus kinase (JAK) inhibitor that has recently been approved for the treatment of PsA by various international regulatory authorities, including the FDA, EMA, and NICE. : In this review, the mechanism of action and the pharmacokinetic properties of tofacitinib are discussed. The data from two large phase III clinical studies evaluating the use of tofacitinib in PsA is also discussed in addition to the findings from other relevant studies. : The clinical data demonstrate significant improvement in disease activity in PsA patients using tofacitinib. There is also an acceptable clinical safety profile for the drug. Tofacitinib has various advantages over several existing drug treatments for PsA including an oral route of administration, a short half-life and a fast onset of action. Consequently, we anticipate that tofacitinib will become an increasingly used targeted synthetic DMARD (tsDMARD) for active PsA over the coming years.
: 银屑病关节炎（PsA）是一种慢性炎症性疾病，与进行性关节破坏和生活质量下降有关。尽管在 PsA 中经常使用疾病修饰抗风湿药物（DMARDs），但在许多研究中对其影响的研究结果存在争议。人们也对它们的安全性和耐受性表示担忧。托法替尼是一种口服 Janus 激酶（JAK）抑制剂，最近已被包括 FDA、EMA 和 NICE 在内的各种国际监管机构批准用于治疗 PsA。: 在这篇综述中，讨论了托法替尼的作用机制和药代动力学特性。还讨论了两项评估托法替尼在 PsA 中应用的大型 III 期临床研究的数据，以及其他相关研究的结果。: 临床数据表明，托法替尼可显著改善 PsA 患者的疾病活动度。该药物也具有可接受的临床安全性特征。与几种现有的 PsA 治疗药物相比，托法替尼具有多种优势，包括口服给药途径、半衰期短和起效迅速。因此，我们预计托法替尼在未来几年将成为治疗活动性 PsA 的越来越常用的靶向合成 DMARD（tsDMARD）。
